Klinicheskaia meditsina最新文献_第3页

Medical staff of the Russian Expeditionary Force and the Honorary Russian Legion in France 在法国的俄罗斯远征军和俄罗斯荣誉军团的医务人员

Klinicheskaia meditsina Pub Date : 2023-09-22 DOI: 10.30629/0023-2149-2023-101-7-8-416-424

V. B. Simonenko, V. G. Abashin, P. E. Krynyukov, P. A. Dulin

引用次数: 0

Diagnosis and surgical treatment of congenital anomalies of the development of the female genital organs 女性生殖器官发育先天性异常的诊断与外科治疗

Klinicheskaia meditsina Pub Date : 2023-09-22 DOI: 10.30629/0023-2149-2023-101-7-8-410-412

A. E. Solovyev, L. F. Pritulo, E. F. Gerashenko, K. S. Toncheva

引用次数: 0

Treatment of patients with chronic thromboembolic pulmonary hypertension 慢性血栓栓塞性肺动脉高压患者的治疗

Klinicheskaia meditsina Pub Date : 2023-09-22 DOI: 10.30629/0023-2149-2023-101-7-8-361-367

O. Ya. Vasiltseva, A. E. Uranov, A. G. Edemskiy, E. N. Kliver, D. S. Grankin, D. A. Sirota, A. B. Romanov, A. M. Chernyavskiy

{"title":"Treatment of patients with chronic thromboembolic pulmonary hypertension","authors":"O. Ya. Vasiltseva, A. E. Uranov, A. G. Edemskiy, E. N. Kliver, D. S. Grankin, D. A. Sirota, A. B. Romanov, A. M. Chernyavskiy","doi":"10.30629/0023-2149-2023-101-7-8-361-367","DOIUrl":"https://doi.org/10.30629/0023-2149-2023-101-7-8-361-367","url":null,"abstract":"The understanding of the tactics for managing patients with pulmonary hypertension (PH) of various etiologies is currently being developed. In August 2022, the European Society of Cardiology adopted new Guidelines for the management of patients with pulmonary hypertension. A separate cohort among them consists of patients with chronic thromboembolic pulmonary hypertension (CTEPH), classifi ed as Group 4 according to the WHO classifi cation. The possibilities of diagnosis, treatment methods, and their availability for this pathology have signifi cantly expanded over the past two decades. The aim of this study is to familiarize physicians with modern methods of treating CTEPH in order to timely refer patients to the most eff ective types of treatment currently available in expert centers in the Russian Federation. Materials and methods . The strategy for searching sources involved analyzing Medline (PubMed) and Scopus databases for the past 20 years using keywords such as diagnostic criteria for chronic thromboembolic pulmonary hypertension, treatment of chronic thromboembolic pulmonary hypertension. To search for additional materials on the topic, the lists of literature in relevant articles and reviews were analyzed.","PeriodicalId":17856,"journal":{"name":"Klinicheskaia meditsina","volume":"62 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136098846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Epigenetic signals in heart failure: new opportunities for early diagnosis and eff ective therapy 心力衰竭的表观遗传信号:早期诊断和有效治疗的新机会

Klinicheskaia meditsina Pub Date : 2023-09-22 DOI: 10.30629/0023-2149-2023-101-7-8-353-360

K. A. Aitbaev, I. T. Murkamilov, V. V. Fomin, I. O. Kudaibergenova, F. A. Yusupov, Z. A. Aidarov

{"title":"Epigenetic signals in heart failure: new opportunities for early diagnosis and eff ective therapy","authors":"K. A. Aitbaev, I. T. Murkamilov, V. V. Fomin, I. O. Kudaibergenova, F. A. Yusupov, Z. A. Aidarov","doi":"10.30629/0023-2149-2023-101-7-8-353-360","DOIUrl":"https://doi.org/10.30629/0023-2149-2023-101-7-8-353-360","url":null,"abstract":"Heart failure (HF) is a severe clinical syndrome associated with signifi cant morbidity and mortality. According to the mechanisms of HF development, it is divided into two main clinical forms: heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF). While eff ective and specifi c treatment methods have been developed for HFrEF, leading to a decrease in the prevalence of this form of HF in recent years, the prognosis for patients with HFpEF remains unfavourable, and eff ective treatment methods do not yet exist. Therefore, the identifi cation of new molecular targets and therapeutic approaches is considered an important task of modern medicine. Data obtained in this fi eld have revealed the key involvement of epigenetic signals in the regulation of transcriptional programs underlying the development of HFpEF, which has contributed to the development of selective epigenetic drugs capable of reversing transcriptional changes and thus delaying or preventing the progression of HFpEF. Further thorough investigation of individual epigenetic landscapes may provide opportunities in the future for the development of personalized epigenetic biomarkers and treatment methods for HFpEF. The aim of this review is to consider the role of epigenetic processing, as well as its diagnostic and therapeutic possibilities in HFpEF.","PeriodicalId":17856,"journal":{"name":"Klinicheskaia meditsina","volume":"44 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136098851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Quality of life in patients after treatment of deep vein thrombosis with regional catheter thrombolysis 局部导管溶栓治疗深静脉血栓患者的生活质量

Klinicheskaia meditsina Pub Date : 2023-09-22 DOI: 10.30629/0023-2149-2023-101-7-8-376-380

B. S. Sukovatykh, A. V. Sereditsky, A. Yu. Grigoryan, M. B. Sukovatykh, V. M. Pashkov

{"title":"Quality of life in patients after treatment of deep vein thrombosis with regional catheter thrombolysis","authors":"B. S. Sukovatykh, A. V. Sereditsky, A. Yu. Grigoryan, M. B. Sukovatykh, V. M. Pashkov","doi":"10.30629/0023-2149-2023-101-7-8-376-380","DOIUrl":"https://doi.org/10.30629/0023-2149-2023-101-7-8-376-380","url":null,"abstract":"The aim of the study was to compare the quality of life in patients after treatment of deep vein thrombosis with regional catheter thrombolysis using alteplase and urokinase, and to compare the results with clinical examination data. Material and methods. The assessment of quality of life and data from a control objective examination were conducted in 32 patients with deep vein thrombosis, divided into two statistically homogeneous groups of 16 individuals each. Alteplase was used for thrombolysis in the fi rst group, while urokinase was used in the second group. The quality of life in patients was evaluated using two questionnaires: SF-36 and CIVIQ-20. The severity of venous disease was determined based on the clinical assessment of venous return impairment. Results . In the fi rst group, the physical component of health according to the SF-36 questionnaire was 56 (49.5; 56.3), the psychological component was 54 (50; 68.8), while in the second group it was 34 (33; 34) and 38 (31.3; 45) respectively. The overall health assessment according to the CIVIQ-20 questionnaire was 20 (10.8; 30) in the fi rst group and 40 (32.8; 43.8) in the second group. In the clinical examination, venous return impairment was absent or mild in 75% of patients in the fi rst group, and equally distributed between mild and severe in 50% of patients in the second group. Conclusion . Alteplase thrombolysis has a more positive impact on the quality of life in patients compared to urokinase.","PeriodicalId":17856,"journal":{"name":"Klinicheskaia meditsina","volume":"118 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136099294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Dermatopathic lymphadenopathy]. [Dermatopathic淋巴结病)。

Klinicheskaia meditsina Pub Date : 2020-02-08 DOI: 10.32388/yw3grw

A. Raben, N. Pokrovskaia, M. A. Reĭzinger, E. N. Unukova

引用次数: 5

[Reiter syndrome].

Klinicheskaia meditsina Pub Date : 2020-02-07 DOI: 10.32388/xzhejo

P. I. Korzhukova

引用次数: 0

[Primary hyperparathyroidism]. 原发性甲状旁腺功能亢进。

Klinicheskaia meditsina Pub Date : 2020-02-07 DOI: 10.32388/j2faj0

A. Kalinin, M. Balabolkin, V. S. Luk'ianchikov, D. N. Nurmanbetov